Please ensure Javascript is enabled for purposes of website accessibility

FDA Accepts Celgene’s Blood Disorder Drug for Review

Summit’s Celgene (Nasdaq: CELG) said Tuesday the U.S. Food and Drug Administration has formalSummit’s Celgene (Nasdaq: CELG) said Tuesday the U.S. Food and Drug Administration has formal

NJBIZ STAFF
Write to the Editorial Department at editorial@njbiz.com.